이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Microbix Biosystems 관리

관리 기준 확인 3/4

Microbix Biosystems' CEO는 Cameron Groome, Jul2017 에 임명되었습니다 의 임기는 7.08 년입니다. 총 연간 보상은 CA$ 476.58K, 85.3% 로 구성됩니다. 85.3% 급여 및 14.7% 보너스(회사 주식 및 옵션 포함). 는 CA$ 1.08M 가치에 해당하는 회사 주식의 2.2% 직접 소유합니다. 1.08M. 경영진과 이사회의 평균 재임 기간은 각각 7.6 년과 17.5 년입니다.

주요 정보

Cameron Groome

최고 경영자

CA$476.6k

총 보상

CEO 급여 비율	85.3%
CEO 임기	7.2yrs
CEO 소유권	2.2%
경영진 평균 재임 기간	7.7yrs
이사회 평균 재임 기간	17.6yrs

최근 관리 업데이트

Recent updates

Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution

Aug 22

Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem

Feb 21

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 17

Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up

Dec 23

Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?

Nov 03

Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?

Jul 22

Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio

May 17

Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook

Dec 27

One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates

Dec 28

Is Microbix Biosystems (TSE:MBX) A Risky Investment?

Oct 14

Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 15

A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)

May 17

Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable

Mar 24

We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt

Jan 29

CEO 보상 분석

Cameron Groome 의 보수는 Microbix Biosystems 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CA$5m
Mar 31 2024	n/a	n/a	CA$4m
Dec 31 2023	n/a	n/a	CA$4m
Sep 30 2023	CA$477k	CA$406k	-CA$39k
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$1m
Dec 31 2022	n/a	n/a	-CA$391k
Sep 30 2022	CA$537k	CA$388k	CA$2m
Jun 30 2022	n/a	n/a	CA$3m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	n/a	n/a	CA$4m
Sep 30 2021	CA$598k	CA$311k	CA$3m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$4m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$363k	CA$305k	-CA$6m
Jun 30 2020	n/a	n/a	-CA$1m
Mar 31 2020	n/a	n/a	-CA$1m
Dec 31 2019	n/a	n/a	-CA$434k
Sep 30 2019	CA$313k	CA$281k	CA$32k
Jun 30 2019	n/a	n/a	-CA$8m
Mar 31 2019	n/a	n/a	-CA$8m
Dec 31 2018	n/a	n/a	-CA$9m
Sep 30 2018	CA$306k	CA$250k	-CA$9m

보상 대 시장: Cameron 의 총 보상 ($USD 350.51K )은 Canadian 시장( $USD 176.07K ).

보상과 수익: Cameron 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Cameron Groome

7.2yrs

테뉴어

CA$476,575

보상

Mr. Cameron L. Groome is Director of Naegis Pharmaceuticals Inc. He serves as an Independent Director at iFabric Corp. since March 30, 2020. Mr. Groome has been the Chief Executive Officer and President of...

리더십 팀

이름	위치	테뉴어	보상	소유권
Cameron Groome	President	7.2yrs	CA$476.58k	2.2% CA$ 990.2k
James Currie	Chief Financial Officer	7.7yrs	CA$312.52k	0.20% CA$ 90.8k
Kenneth Hughes	Chief Operating Officer	5.3yrs	CA$312.58k	0.33% CA$ 150.1k
Mark Luscher	Senior Vice President of Scientific Affairs	16.8yrs	CA$277.11k	0.27% CA$ 122.0k
Philip Casselli	Senior Vice President of Sales	11.8yrs	CA$292.92k	0.38% CA$ 172.1k
Christopher Lobb	Compliance Officer	no data	데이터 없음	데이터 없음

7.7yrs

평균 재임 기간

경험이 풍부한 관리: MBX 의 관리팀은 노련하고 경험 (평균 재직 기간 7.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cameron Groome	President	12.5yrs	CA$476.58k	2.2% CA$ 990.2k
Mark Cochran	Independent Director	21.9yrs	데이터 없음	0.40% CA$ 181.3k
Joseph Renner	Independent Director	21.6yrs	데이터 없음	6.93% CA$ 3.1m
Martin Marino	Independent Chairman of the Board	15.6yrs	데이터 없음	1.08% CA$ 484.0k
Peter Blecher	Independent Director	18.8yrs	데이터 없음	2.07% CA$ 928.8k
Vaughn Embro-Pantalony	Independent Director	17.6yrs	데이터 없음	1.26% CA$ 566.5k
Jennifer Stewart	Independent Director	2.5yrs	데이터 없음	0.010% CA$ 4.6k

17.6yrs

평균 재임 기간

경험이 풍부한 이사회: MBX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 17.5 년).

Microbix Biosystems 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Microbix Biosystems Inc., Annual General Meeting, Mar 29, 2023

Insufficient new directors

President recently sold CA$70k worth of stock

President exercised options to buy CA$191k worth of stock.

Recent updates

Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution

Third quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.006 loss in 3Q 2023)

Microbix Biosystems Inc. to Report Q3, 2024 Results on Aug 13, 2024

Microbix Biosystems Inc. Presents HCV FLOQSwab Format Test Control at ADLM

Second quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 2Q 2023)

Microbix Biosystems Inc. to Report Q2, 2024 Results on May 15, 2024

Microbix Biosystems Inc. Unveils Test Controls for Head and Neck Cancer

New minor risk - Insider selling

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

First quarter 2024 earnings released: EPS: CA$0.018 (vs CA$0.009 loss in 1Q 2023)

Microbix Biosystems Inc. to Report Q1, 2024 Results on Feb 14, 2024

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up

Full year 2023 earnings: Revenues miss analyst expectations

Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024

Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.005 profit in 3Q 2022)

Microbix Successfully Upgrades Logistics Software Systems Achieves “Go-Live” with New ERP and eQMS Solutions

Microbix Biosystems Inc. Presents Results of STI Test Controls at AACC

Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?

Microbix Biosystems Inc. Presents Results of STI Test Controls at ASM Microbe Microbe FLOQ

Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0.005 in 2Q 2022)

First quarter 2023 earnings: Revenues miss analyst expectations

Microbix Biosystems Inc. Launches QAP to Support "Monkeypox" Testing

Microbix Biosystems Inc., Annual General Meeting, Mar 29, 2023

Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$1.13

Insufficient new directors

Microbix Biosystems Inc. Presenting Test-Workflow Validation Results At EMMD

President recently sold CA$70k worth of stock

President exercised options to buy CA$191k worth of stock.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet

President exercised options to buy CA$182k worth of stock.

Microbix Biosystems Inc. Presenting Test Validation Methods at AACC

Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals

Consensus EPS estimates fall by 28%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Microbix Biosystems Inc. Provides Earnings Guidance for the Fiscal Year 2022

Microbix Biosystems Inc. to Present Performance Results of its Quality Assessment Product at the 2022 Clinical Virology Symposium of the American Society for Microbiology

Price target decreased to CA$1.50

Insufficient new directors

President exercised options to buy CA$206k worth of stock.

Microbix Biosystems Inc. Presents HPV Product Results at EUROGIN

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$1.50

Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly

Microbix Biosystems Inc. Launches Omicron Variant Test Control

President exercised options to buy CA$274k worth of stock.

One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Microbix Biosystems Inc. Launches Multiplex Respiratory PCR-Test Control

Insufficient new directors

Chief Financial Officer recently sold CA$68k worth of stock

Independent Chairman of the Board exercised options to buy CA$426k worth of stock.

Independent Director exercised options to buy CA$115k worth of stock.

Independent Director exercised options to buy CA$117k worth of stock.

Is Microbix Biosystems (TSE:MBX) A Risky Investment?

President exercised options to buy CA$107k worth of stock.

Microbix Biosystems Inc. Presenting Product Results At AACC

Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2021 earnings released: EPS CA$0.013 (vs CA$0.004 loss in 3Q 2020)

Microbix Biosystems Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021